drugset / Trial / NCT00386581

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

NCT00386581

Phase 3 Completed 105 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is designed to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy (in the morning). It incorporates a 6-week acute treatment period and a 2-week discontinuation phase. The assessments in this study include a standard assessment of ADHD symptomatology using a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition™, investigator-administered rating scale.

Timeline

Start
2004-07
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified